Danaher (NYSE:DHR) Releases Earnings Results, Beats Estimates By $0.26 EPS

Danaher (NYSE:DHR - Get Free Report) announced its quarterly earnings data on Tuesday. The conglomerate reported $1.88 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.26, Zacks reports. Danaher had a net margin of 16.33% and a return on equity of 10.82%. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.58 billion. Danaher updated its FY 2025 guidance to 7.600-7.750 EPS.

Danaher Trading Down 0.6 %

Danaher stock traded down $1.25 during trading on Friday, reaching $195.25. 169,218 shares of the company were exchanged, compared to its average volume of 3,341,432. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The company has a market capitalization of $139.55 billion, a P/E ratio of 36.89, a PEG ratio of 2.66 and a beta of 0.86. The stock's 50 day simple moving average is $201.01 and its two-hundred day simple moving average is $225.07. Danaher has a 52-week low of $171.00 and a 52-week high of $281.70.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.66%. The ex-dividend date is Friday, March 28th. This is an increase from Danaher's previous quarterly dividend of $0.27. Danaher's dividend payout ratio is 24.85%.

Analyst Ratings Changes

A number of brokerages recently weighed in on DHR. UBS Group lowered their price objective on shares of Danaher from $275.00 to $240.00 and set a "buy" rating on the stock in a research report on Wednesday. Guggenheim restated a "buy" rating and set a $250.00 target price on shares of Danaher in a research report on Wednesday. Stifel Nicolaus upgraded shares of Danaher from a "hold" rating to a "buy" rating and set a $260.00 price target on the stock in a research note on Friday, March 14th. Wells Fargo & Company reduced their target price on shares of Danaher from $280.00 to $240.00 and set an "equal weight" rating for the company in a report on Thursday, January 30th. Finally, Citigroup reissued a "buy" rating on shares of Danaher in a research note on Monday, April 7th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $264.40.

Insider Transactions at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the company's stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 11.10% of the company's stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.